205 related articles for article (PubMed ID: 26317883)
1. HCS campaign to identify selective inhibitors of IL-6-induced STAT3 pathway activation in head and neck cancer cell lines.
Johnston PA; Sen M; Hua Y; Camarco DP; Shun TY; Lazo JS; Wilson GM; Resnick LO; LaPorte MG; Wipf P; Huryn DM; Grandis JR
Assay Drug Dev Technol; 2015 Sep; 13(7):356-76. PubMed ID: 26317883
[TBL] [Abstract][Full Text] [Related]
2. High-content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines.
Johnston PA; Sen M; Hua Y; Camarco D; Shun TY; Lazo JS; Grandis JR
Assay Drug Dev Technol; 2014; 12(1):55-79. PubMed ID: 24127660
[TBL] [Abstract][Full Text] [Related]
3. Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes.
Leibowitz MS; Andrade Filho PA; Ferrone S; Ferris RL
Cancer Immunol Immunother; 2011 Apr; 60(4):525-35. PubMed ID: 21207025
[TBL] [Abstract][Full Text] [Related]
4. High Content Imaging Assays for IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines.
Johnston PA; Sen M; Hua Y; Camarco DP; Shun TY; Lazo JS; Grandis JR
Methods Mol Biol; 2018; 1683():229-244. PubMed ID: 29082496
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma.
Bharadwaj U; Eckols TK; Xu X; Kasembeli MM; Chen Y; Adachi M; Song Y; Mo Q; Lai SY; Tweardy DJ
Oncotarget; 2016 May; 7(18):26307-30. PubMed ID: 27027445
[TBL] [Abstract][Full Text] [Related]
6. Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane).
Chakravarti N; Myers JN; Aggarwal BB
Int J Cancer; 2006 Sep; 119(6):1268-75. PubMed ID: 16642480
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of selective inhibitors of IL-6 induced STAT3 pathway in head and neck cancer cell lines.
Sen M; Johnston PA; Pollock NI; DeGrave K; Joyce SC; Freilino ML; Hua Y; Camarco DP; Close DA; Huryn DM; Wipf P; Grandis JR
J Chem Biol; 2017 Jul; 10(3):129-141. PubMed ID: 28684999
[TBL] [Abstract][Full Text] [Related]
8. (-)-Epigallocatechin gallate induces Fas/CD95-mediated apoptosis through inhibiting constitutive and IL-6-induced JAK/STAT3 signaling in head and neck squamous cell carcinoma cells.
Lin HY; Hou SC; Chen SC; Kao MC; Yu CC; Funayama S; Ho CT; Way TD
J Agric Food Chem; 2012 Mar; 60(10):2480-9. PubMed ID: 22313388
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.
Li C; Zang Y; Sen M; Leeman-Neill RJ; Man DS; Grandis JR; Johnson DE
Mol Cancer Ther; 2009 Aug; 8(8):2211-20. PubMed ID: 19638453
[TBL] [Abstract][Full Text] [Related]
10. Absence of STAT1 disturbs the anticancer effect induced by STAT3 inhibition in head and neck carcinoma cell lines.
Shim SH; Sung MW; Park SW; Heo DS
Int J Mol Med; 2009 Jun; 23(6):805-10. PubMed ID: 19424608
[TBL] [Abstract][Full Text] [Related]
11. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
[TBL] [Abstract][Full Text] [Related]
12. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of JAK2/STAT3 reduces tumor-induced angiogenesis and myeloid-derived suppressor cells in head and neck cancer.
Liu JF; Deng WW; Chen L; Li YC; Wu L; Ma SR; Zhang WF; Bu LL; Sun ZJ
Mol Carcinog; 2018 Mar; 57(3):429-439. PubMed ID: 29215754
[TBL] [Abstract][Full Text] [Related]
14. Guggulsterone (GS) inhibits smokeless tobacco and nicotine-induced NF-κB and STAT3 pathways in head and neck cancer cells.
Macha MA; Matta A; Chauhan SS; Siu KW; Ralhan R
Carcinogenesis; 2011 Mar; 32(3):368-80. PubMed ID: 21177768
[TBL] [Abstract][Full Text] [Related]
15. Development and utilization of activated STAT3 detection assays for screening a library of secreted proteins.
Fursov N; Gates IV; Panavas T; Giles-Komar J; Powers G
Assay Drug Dev Technol; 2011 Aug; 9(4):420-9. PubMed ID: 21294636
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of STAT3 in head and neck cancer requires p38 MAPKinase, whereas phosphorylation of STAT1 occurs via a different signaling pathway.
Riebe C; Pries R; Schroeder KN; Wollenberg B
Anticancer Res; 2011 Nov; 31(11):3819-25. PubMed ID: 22110204
[TBL] [Abstract][Full Text] [Related]
17. Sensitization of head and neck cancer to cisplatin through the use of a novel curcumin analog.
Abuzeid WM; Davis S; Tang AL; Saunders L; Brenner JC; Lin J; Fuchs JR; Light E; Bradford CR; Prince ME; Carey TE
Arch Otolaryngol Head Neck Surg; 2011 May; 137(5):499-507. PubMed ID: 21576562
[TBL] [Abstract][Full Text] [Related]
18. Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines.
Bill MA; Nicholas C; Mace TA; Etter JP; Li C; Schwartz EB; Fuchs JR; Young GS; Lin L; Lin J; He L; Phelps M; Li PK; Lesinski GB
PLoS One; 2012; 7(8):e40724. PubMed ID: 22899991
[TBL] [Abstract][Full Text] [Related]
19. STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell.
Bu LL; Zhao ZL; Liu JF; Ma SR; Huang CF; Liu B; Zhang WF; Sun ZJ
Oncotarget; 2015 Dec; 6(39):41944-58. PubMed ID: 26556875
[TBL] [Abstract][Full Text] [Related]
20. Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer.
Peyser ND; Freilino M; Wang L; Zeng Y; Li H; Johnson DE; Grandis JR
Oncogene; 2016 Mar; 35(9):1163-9. PubMed ID: 25982282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
